Alkeon Capital Management LLC Buys 45,000 Shares of argenx SE (NASDAQ:ARGX)

Alkeon Capital Management LLC increased its position in argenx SE (NASDAQ:ARGX) by 15.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 345,000 shares of the company’s stock after acquiring an additional 45,000 shares during the quarter. Alkeon Capital Management LLC’s holdings in argenx were worth $187,018,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. lifted its stake in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. J.Safra Asset Management Corp increased its holdings in shares of argenx by 590.0% in the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after purchasing an additional 59 shares during the period. GAMMA Investing LLC raised its position in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of argenx in the second quarter worth $76,000. Finally, Cromwell Holdings LLC boosted its stake in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ARGX shares. Wells Fargo & Company upped their target price on argenx from $547.00 to $639.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. raised their target price on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. William Blair raised shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Raymond James restated a “strong-buy” rating and set a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. Finally, Guggenheim upped their target price on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $630.42.

argenx Trading Up 1.2 %

Shares of NASDAQ:ARGX opened at $614.59 on Friday. The company has a market cap of $37.10 billion, a price-to-earnings ratio of -698.40 and a beta of 0.61. argenx SE has a 12 month low of $327.73 and a 12 month high of $620.28. The company has a 50-day moving average price of $562.49 and a 200-day moving average price of $493.62.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter last year, the business posted ($1.25) EPS. As a group, research analysts forecast that argenx SE will post 2.2 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.